Pharmabiz

Bristol announces positive results from phase 3 CheckMate -648 trial of Opdivo plus chemotherapy & Opdivo plus Yervoy to treat unresectable advanced or metastatic ESCC

Bristol Myers Squibb announced positive topline results from the phase 3 CheckMate -648 trial evaluating treatment with Opdivo (nivolumab) plus chemotherapy or Opdivo plus Yervoy (ipilimumab) in ...
Seeking Alpha

Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy...

Patients experienced a 38% reduction in the risk of disease progression or death when treated with Opdivo plus Yervoy versus Opdivo monotherapy across all lines of therapy at median 47 months of ...
Monthly Prescribing Reference

Opdivo-Based Regimens Approved as First-Line Treatments for Esophageal Cancer

Swallowable sampling device combined with methylation biomarker panel IDs Barrett esophagus. The approvals are based on data from the phase 3 CheckMate-648 trial, which included 970 adults with ...
Seeking Alpha

U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor ...

Given over three- to five-minutes, Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety profile to intravenous Opdivo in the Phase 3 CheckMate-67T trial 1,3 Opdivo and Opdivo ...
Pharmabiz

BMS announces positive results from phase 3 CheckMate -9LA trial of Opdivo plus Yervoy with two cycles of chemotherapy for patients with metastatic NSCLC

Bristol Myers Squibb (BMS) announced four-year follow-up results from the phase 3 CheckMate -9LA trial demonstrating durable, long-term survival benefits with Opdivo (nivolumab) plus Yervoy ...